A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
The purpose of this study is to find out if an investigational drug, called ADP-A2M4, is safe and how well it works in attacking Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS) cancer cells. The study involves taking certain types of immune cells from the blood, called T cells, and changing them in a laboratory before putting them back into the bloodstream, with the aim of helping them to attack and kill cancer cells. It is hoped to learn if these genetically changed T cells are safe and work to kill these cancer cell types.
This study is closed
Gary Schwartz, MD
|Are you between the ages of 16 to 75?
|Have you been diagnosed with advanced synovial sarcoma or myxoid liposarcoma / myxoid round cell liposarcoma?